인벤티지랩

389470KOSDAQ자연과학 및 공학 연구개발업

46.6 / 100

Reference Date: 2026-04-13

Financial Score11.0 / 40

News Sentiment15.6 / 25

Momentum6.0 / 20

Disclosure14.0 / 15

AI Analysis: PBR raises overvaluation concerns, Operating Profit is on a declining trend. Plunged 37.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InventiZ Lab is a DDS (Drug Delivery System) platform company leveraging microfluidics-based Laminar-FLUIDigm™ technology to develop long-acting injectables and gene delivery solutions. It utilizes the IVL-DrugFluidic® platform for improved new drug development and the IVL-GeneFluidic® platform for LNP formulation services for mRNA vaccines, alongside expanding CDMO (Contract Development and Manufacturing Organization) operations. The company currently produces and sells Durahart SR-3 injectable solution and is advancing multiple drug candidates, including IVL3001, IVL3003, and IVL3004, through various clinical trials.

Number of Employees

73people

Average Salary

44.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

10.15Industry Average 3.820.0Point

2.7x industry avg (risky)

ROE

-28.06Industry Average -32.113.5Point

Below industry avg

Debt Ratio

12.37Industry Average 7.520.5Point

1.6x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲117.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼34.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -91.6% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 0Negative 0Average Sentiment Score 75

Positive
"항체의약품 고농축 기술 개발…집에서 암 치료하는 시대 온다"
인벤티지랩이 항체의약품 고농축 기술 'IVL-바이오플루이딕'을 개발하여 환자 편의성을 개선하고 집에서 암 치료가 가능한 시대를 열 것으로 기대됩니다.
Positive
[바이오 톺아보기]'표적 세포 전달' 테르나, 차세대 기술 정조준
인벤티지랩이 LNP 플랫폼 기술을 활용하여 비만약 개발 등 오픈 이노베이션을 확대하고 있으며, mRNA 기술의 확장 가능성에 주목하고 있습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (54%)

Current 61,800Won52-week high 99,50052-week low 17,000

1-month return0.0Point

1m -37.58% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

15 totalPositive 2Neutral 13Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
Neutral주식등의대량보유상황보고서(일반)2026-04-02
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral주식매수선택권부여에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31